|Ms. Maria Zannes J.D.||Founder, Pres, CEO & Director||227.2k||N/A||1956|
|Dr. Vivienne I. Rebel M.D., Ph.D.||Exec. VP and Chief Medical & Science Officer||236.59k||N/A||1965|
|Mr. Michael Edwards CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1967|
|Mr. Xavier T. Reveles M.S.||VP of Operations||N/A||N/A||N/A|
|Mr. Timothy P. Zannes J.D.||Exec. VP, Sec. & Gen. Counsel||N/A||N/A||1953|
|Dr. William Bauta Ph.D.||Sr. VP of R&D - Therapeutics||N/A||N/A||N/A|
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. ’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.